Fig. 2
From: Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Model structures. A. Main health state. (1) Starting state: Patients whose BMD T-score improved from below − 2.5 to -2.5 ≤ T-score<-2.0 with denosumab; (2) T-score decrease: Patients who rebound to BMD T-score below − 2.5; (3) T-score increase: Patients who T-score increased over − 2.0 or over − 2.5 ≤ T-score<-2.0 after subsequent therapy; (4) All-cause death; B. Sub-health state. Sub-health state probabilities differed according to the main health state. (1) Well (no new fracture); (2) Vertebral fracture; (3) Non-vertebral fracture; (4) Fracture-related death